October 29, 2021
October 29, 2021 – The U.S. FDA has approved Scemblix® (asciminib) to treat adults diagnosed with Philadelphia chromosome–positive chronic myeloid leukemia
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
News
October 29, 2021
October 29, 2021 – VuityTM (pilocarpine HCI ophthalmic solution) 1.25% has been approved to treat presbyopia. It is the first and only eye drop to receive U.S. FDA approval
October 27, 2021
October 27, 2021 – The U.S. FDA has expanded the indication for cutaquig® [immune globulin subcutaneous (human)-hipp] 16.5% solution to include
October 25, 2021
October 25, 2021 – XipereTM (triamcinolone acetonide injectable suspension) has been approved by the U.S. FDA for suprachoroidal use to treat macular edema
October 25, 2021
September 25 – Eli Lilly has recalled one lot of Glucagon® Emergency Kit for Low Blood Sugar (Glucagon for Injection, 1mg per vial; Diluent for Glucagon, 1mL syringe)
October 22, 2021
October 22, 2021 – Oncopeptides will withdraw Pepaxto® (melphalan flufenamide) from the United States market after a post-marketing clinical trial raised safety concerns
October 22, 2021
October 22, 2021 – Cyltezo® (adalimumab-adbm – Boehringer Ingelheim) has received U.S. FDA approval to reduce the signs and symptoms of moderately to severely
October 20, 2021
October 20, 2021 – The U.S. FDA has amended the emergency use authorizations (EUAs) for COVID-19
vaccines to expand the use of booster shots in eligible individuals